Nobuo Itoh

Title: Nobuo Itoh: Innovator in Cephem Compounds

Introduction

Nobuo Itoh is a distinguished inventor based in Yokohama, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cephem compounds. With a total of 2 patents to his name, Itoh's work has advanced the understanding and application of these important chemical compounds.

Latest Patents

Itoh's latest patents include innovative processes for preparing novel cephem compounds. One of his notable inventions is the "Polychalcogen ester of cephem compound, process for preparing the same." This patent describes a unique ester of a cephem compound that features a carboxyl group at the 4-position in the nucleus. The process involves reacting a cephem carboxylic acid or its salt with a halogenide. Additionally, he has developed a method for removing the protective group for the carboxyl group in the nucleus of a cephem compound by contacting it with an alcohol or an organic solvent in the presence of a Lewis acid.

Another significant patent is the "Process for preparing cephalosporin esters in the presence of liquid." This process outlines the preparation of a cephalosporin ester by reacting an organic halide or an alcohol with a cephalosporin acid, a cephalosporin acid halide, or a salt thereof in the presence of liquid sulfur dioxide.

Career Highlights

Nobuo Itoh is currently associated with Meiji Seika Kaisha, Ltd., where he continues to innovate in the field of pharmaceuticals. His work has not only contributed to the scientific community but has also had practical applications in medicine.

Collaborations

Throughout his career, Itoh has collaborated with notable colleagues, including Shigeo Seki and Ken Nishihata. These collaborations have further enriched his research and development efforts.

Conclusion

Nobuo Itoh's contributions to the field of cephem compounds exemplify the impact of innovative thinking in pharmaceuticals. His patents reflect a commitment to advancing medical science and improving therapeutic options.